European Psychiatry - Volume 41 - April 2017

376 / 916

S372 25th European congress of psychiatry / European Psychiatry 41S (2017) S365–S404
Aims To compare the threshold for sweet (test) and salt (con-
trol) after 1 and 4 weeks of SSRI escitalopram therapy in depressed
patients.
Methods The project was approved by the institutional ethics
committee. Following informed consent, depressed patients were
initiated on escitalopram 10mg/d (increased to 15 or 20mg, if
required after 1 week,). Taste recognition threshold, intensity and
pleasantness were measured for sweet and salt. Each tastant was
made −1 to −3 (100mM–1mM). Regional recognition thresholds
were determined at the tip of the tongue using a cotton bud well
soaked in the tastant.
Results Three males and 4 females of mean ages 39.1 years com-
pleted the study. There was significant shift to the left for sweet
thresholds between days 0 and 7, and 7 and 28 [F(Dfn, Dfd) = 9.242
(4.162) P < 0.0001]. A similar shift to the left was seen for salt but
day 7 only [F(Dfn, Dfd) = 6.213 (4.162)].
Conclusion The increase in serotonin throughput as envisaged
through SSRI treatment was paralleled by decrease in sweet thresh-
olds.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0771
Metabolic outcomes of Red yeast rice
administration in patients treated
with second-generation
antipsychotics
G.M. Troili ∗, A. Bruno , G. Pandolfo , M. Crucitti , R.A. Zoccali ,
M.R.A. Muscatello
University of Messina, Psychiatric Unit, Department of Biomedical
and Dental Sciences and Morphofunctional Imaging, Messina, Italy
∗ Corresponding author.
Rationale Second-generation antipsychotics (SGAs) are notori-
ously associated with a wide range of metabolic adverse effects,
and their chronic use is related with an increased risk for the devel-
opment of metabolic syndrome (MS). The nutraceutical approach
to the management of MS might be a promising strategy in the
prevention of cardio-metabolic risk. In this context, Red yeast rice
(RYR) have been shown to have a lipid lowering effect in an increas-
ing number of clinical studies.
Objectives The present study was aimed to explore the efficacy
and safety of RYR treatment on metabolic parameters in a sample
of subjects receiving atypical antipsychotics.
Methods Ten outpatients treated with atypical APs assumed RYR
at single daily dose of 200mg/day for 30 days. Total cholesterol,
high-density lipoprotein cholesterol (HDL), low-density lipopro-
tein cholesterol (LDL), triglycerides, fasting levels of glucose, and
glycated hemoglobin were determined.
Results RYR administration non-resulted in a statistically sig-
nificant reduction of metabolic parameters in the study sample.
However, a trend for total cholesterol (T0 vs. T1: 159.6 vs.
145.6) and LDL (T0 vs. T1: 94.1 vs. 77.6) decrease was
observed.
Conclusions Our findings in patients receiving atypical antipsy-
chotics did not confirm the beneficial effect of RYS on lipemic
profiles previously found in subjects who do not take this
class of drugs. Further clinical trials with adequately-powered
and well-designed methodology are needed to better explore
the RYS effectiveness on the SGAs-induced metabolic side
effects.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0772
Preserved cognition and reduced
age-related cognitive decline during
treatment with angiotensin II receptor
blockers: A 20-year follow-up study
D. Wincewicz ∗, T. Tolmunen , A.K. Brem , J. Kauhanen ,
S. Lehto
1 Medical University of Bialystok, Department of Clinical
Pharmacology, Bialystok, Poland
2 Medical University of Bialystok, Department of Psychiatry,
Bialystok, Poland
3 University of Eastern Finland, Institute of Clinical Medicine, Kuopio,
Finland
4 University of Eastern Finland, Department of Psychiatry, Kuopio,
Finland
5 Max Planck Institute of Psychiatry, Department of
Neuropsychology, Munich, Germany
6 BIDMC Harvard Medical School, Berenson–Allen Center for
Noninvasive Brain Stimulation, Department of Neurology, Boston,
USA
7 University of Oxford, Department of Experimental Psychology,
Oxford, United Kingdom
8 University of Eastern Finland, Institute of Public Health and Clinical
Nutrition, Kuopio, Finland
∗ Corresponding author.
Introduction Modulators of the brain renin-angiotensin system
(RAS) have been shown to improve cognitive functioning in sev-
eral animal models of neuropsychiatric disorders. Moreover, the
brain RAS has been considered a new target for the treatment of
Alzheimer’s disease (AD). However, there are no population-based
follow-up studies supporting this hypothesis.
Objectives Cross-sectional and prospective relationships
between cognitive decline and ARB treatment were exam-
ined in the population-based Kuopio Ischemic Heart Disease Risk
Factor Study.
Aims To evaluate procognitive/antidementia capacity of orally
delivered angiotensin II receptor blockers (ARB).
Methods The study was conducted on a sample of 1774 sub-
jects (920 females, 854 males; age range at baseline: 42–61 years)
from Eastern Finland. An established cutoff score of at least 2-
point decrease in the Mini Mental State Examination over a 9-year
follow-up was used to detect age-related cognitive decline in
the cross-sectional setting. In the prospective setting, a hospital
discharge diagnosis of dementia/AD was used as outcome vari-
able. Cross-sectional relationships were determined with logistic
regression and prospective analyses were conducted with the Cox
proportional hazardsmodel (both adjusted for relevant background
variables).
Results Cross-sectional analysis displayed a decrease of the odds
of cognitive decline ( n = 87; 4.9% of participants) in those with ARB
treatment; OR = 0.445, 95% CI: 0.22–0.90, P = 0.024. Furthermore, in
the prospective setting, the risk of dementia/AD diagnosis (n = 149;
8.4% of participants) was significantly reduced in ARB treated par-
ticipants; HR = 0.621, 95% CI: 0.40–0.98, P = 0.038.
Conclusions ARB treatment is associatedwith a decreased risk for
age-related cognitive decline and dementia/AD manifestation.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0773
The effect of Qing Huan Ling on the
hypoglutamatergic schizophrenia
model in mice
Y. Zhang ∗, F. Liu , Z. Dai , Q. Wu
1 Xi’an Mental Health Center, Pharmacy Lab, China